Skip to Main content Skip to Navigation
Journal articles

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

Abstract : Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is termed clonal hematopoiesis of indeterminate potential (CHIP) and is associated with adverse outcomes. Targeted sequencing of the stem cell product from 629 MM patients treated by ASCT at the Dana-Farber Cancer Institute (2003-2011) detects CHIP in 136/629 patients (21.6%). The most commonly mutated genes are DNMT3A, TET2, TP53, ASXL1 and PPM1D. Twenty-one from fifty-six patients (3.3%) receiving first-line IMiD maintenance develop a therapy-related myeloid neoplasm (TMN). However, regardless of CHIP status, the use of IMiD maintenance associates with improved PFS and OS. In those not receiving IMiD maintenance, CHIP is associated with decreased overall survival (OS) (HR:1.34, p = 0.02) and progression free survival (PFS) (HR:1.45, p < 0.001) due to an increase in MM progression.
Complete list of metadatas

Cited literature [66 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02880831
Contributor : Myriam Bodescot <>
Submitted on : Thursday, June 25, 2020 - 11:39:18 AM
Last modification on : Thursday, June 25, 2020 - 11:57:50 AM
Long-term archiving on: : Wednesday, September 23, 2020 - 4:13:10 PM

File

s41467-020-16805-5.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Tarek Mouhieddine, Adam Sperling, Robert Redd, Jihye Park, Matthew Leventhal, et al.. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩. ⟨inserm-02880831⟩

Share

Metrics

Record views

38

Files downloads

52